Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Oil Services ETF
OIH
iShares US Telecommunications ETF
IYZ
4
ProShares Ultra Materials
UYM
5
Energy Select Sector SPDR Fund
XLE
US Stock MarketDetailed Quotes
Connect Biopharma (CNTB)
- 2.900
- -0.030-1.02%
Close Feb 19 16:00 ET
- 2.850
- -0.050-1.72%
Post 17:07 ET
162.12MMarket Cap-3.26P/E (TTM)
2.970High2.701Low68.94KVolume2.970Open2.930Prev Close197.39KTurnover0.40%Turnover RatioLossP/E (Static)55.90MShares3.28052wk High2.93P/B49.81MFloat Cap0.51052wk Low--Dividend TTM17.18MShs Float29.274Historical High--Div Yield TTM9.20%Range %0.510Historical Low2.863Avg Price1Lot Size
CNTB Stock Chart
After-Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
CNTB Orderflow
Unit: --
CNTB Orderflow Trend
IntradayDayWeekMonth
No Data
Connect Biopharma (CNTB) News
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 With Advancements in Biologics and JAK Inhibitors | DelveInsight
3 Promising Penny Stocks With Market Caps Up To $400M
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Context Therapeutics (CNTX) and Connect Biopharma Holdings (CNTB)
Analysts' Top Healthcare Picks: Context Therapeutics (CNTX), Connect Biopharma Holdings (CNTB)
BTIG Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $10
Connect Biopharma (CNTB) Stock Forum
$Connect Biopharma (CNTB.US)$ Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of Its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China. Eligible for upto 110 million in milestone payments
5
$Connect Biopharma (CNTB.US)$
Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Wednesday, 9th July at 9:00 am
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ: CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflamma...
Connect Biopharma's Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Wednesday, 9th July at 9:00 am
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ: CNTB) ("Connect Biopharma", "Connect", or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflamma...
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)